{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:15:52Z","timestamp":1782882952385,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I6565-B, T996-B30"],"award-info":[{"award-number":["I6565-B, T996-B30"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anti-IgLON5 disease is a rare chronic autoimmune disorder characterized by IgLON5 autoantibodies predominantly of the IgG4 subclass. Distinct pathogenic effects were described for anti-IgLON5 IgG1 and IgG4, however, with uncertain clinical relevance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>IgLON5-specific IgG1-4 levels were measured in 46 sera and 20 cerebrospinal fluid (CSF) samples from 13 HLA-subtyped anti-IgLON5 disease patients (six females, seven males) using flow cytometry. Intervals between two consecutive serum or CSF samplings (31 and 10 intervals, respectively) were categorized with regard to the immunomodulatory treatment active at the end of the interval, changes of anti-IgLON5 IgG1 and IgG4 levels, and disease severity.\u00a0Intrathecal anti-IgLON5 IgG4 synthesis (IS) was assessed using a quantitative method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age at onset was 66 years (range: 54\u201375), disease duration 10 years (range: 15\u2013156 months), and follow-up 25 months (range: 0\u201383). IgLON5-specific IgG4 predominance was observed in 38 of 46 (83%) serum and 11 of 20 (55%) CSF samples. Anti-IgLON5 IgG4 levels prior clinical improvement in CSF but not serum were significantly lower than in those prior stable\/progressive disease. Compared to IgLON5 IgG4 levels in serum, CSF levels in HLA-DRB1*10:01 carriers were significantly higher than in non-carriers. Indeed, IgLON5-specific IgG4 IS was demonstrated not only in four of five HLA-DRB1*10:01 carriers but also in one non-carrier. Immunotherapy was associated with decreased anti-IgGLON5 IgG serum levels. In CSF, lower anti-IgLON5 IgG was associated with immunosuppressive treatments used in combination, that is, corticosteroids and\/or azathioprine plus intravenous immunoglobulins or rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings might indicate that CSF IgLON5-specific IgG4 is\u00a0frequently produced intrathecally, especially in HLA-DRB1*10:01 carriers.\u00a0Intrathecally produced IgG4 may be clinically relevant. While many\u00a0immunotherapies reduce serum IgLON5 IgG levels, more intense immunotherapies induce clinical improvement and may be able to target intrathecally produced anti-IgLON5 IgG. Further studies need to confirm whether anti-IgLON5 IgG4 IS is a suitable prognostic and predictive biomarker in anti-IgLON5 disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1376456","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T04:52:46Z","timestamp":1715835166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Inga","family":"Koneczny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Macher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hutterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seifert-Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Berger-Sieczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Blaabjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Breu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Dreyhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia Almeida","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Erdler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Fae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Frommlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Heidbreder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"H\u00f6gl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herburg","family":"Liendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette S.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Reinecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Ricken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"S\u00fc\u00dfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio A. G.","family":"Teive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Gaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lewerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"H\u00f6ftberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000962","article-title":"Anti-igLON5 disease: A new bulbar-onset motor neuron mimic syndrome","volume":"8","author":"Werner","year":"2021","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00329","article-title":"IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes","volume":"9","author":"Montagna","year":"2018","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000651","article-title":"Anti-IGLON5 disease: A new case without neuropathologic evidence of brainstem tauopathy","volume":"7","author":"Erro","year":"2020","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25857","article-title":"Effects of igLON5 antibodies on neuronal cytoskeleton: A link between autoimmunity and neurodegeneration","volume":"88","author":"Landa","year":"2020","journal-title":"Ann Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease","volume":"146","author":"Gruter","year":"2023","journal-title":"Brain"},{"key":"B8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","article-title":"Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome","volume":"13","author":"Sabater","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151574","article-title":"Patients\u2019 IgLON5 autoantibodies interfere with IgLON5-protein interactions","volume":"14","author":"Landa","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00804","article-title":"Cerebrospinal fluid findings in patients with autoimmune encephalitis-A systematic analysis","volume":"10","author":"Blinder","year":"2019","journal-title":"Front Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.2956","article-title":"Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response","volume":"72","author":"Leypoldt","year":"2015","journal-title":"JAMA Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001137","article-title":"Increased intrathecal B and plasma cells in patients with anti-igLON5 disease: A case series","volume":"9","author":"Strippel","year":"2022","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001086","article-title":"CSF findings in acute NMDAR and LGI1 antibody-associated autoimmune encephalitis","volume":"8","author":"Durr","year":"2021","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/biom11081131","article-title":"Transportation of single-domain antibodies through the blood\u2013brain barrier","volume":"11","author":"Ruiz-L\u00f3pez","year":"2021","journal-title":"Biomolecules"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02625-6","article-title":"Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease","volume":"146","author":"Berger-Sieczkowski","year":"2023","journal-title":"Acta Neuropathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(15)60445-7","article-title":"IgLON5 autoimmunity and abnormal behaviours during sleep","volume":"385","author":"Hogl","year":"2015","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01056","article-title":"Anti-igLON5 disease: A case with 11-year clinical course and review of the literature","volume":"10","author":"Nissen","year":"2019","journal-title":"Front Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease","volume":"146","author":"Gruter","year":"2022","journal-title":"Brain"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012639","article-title":"Frequency and characterization of movement disorders in anti-igLON5 disease","volume":"97","author":"Gaig","year":"2021","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000763","article-title":"Antibodies to nodal\/paranodal proteins in paediatric immune-mediated neuropathy","volume":"7","author":"De Simoni","year":"2020","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr Neuropharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000605","article-title":"HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease","volume":"6","author":"Gaig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz1029","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs","volume":"184","author":"Reiber","year":"2001","journal-title":"J Neurol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1193015","article-title":"Clinical associations and characteristics of the polyspecific intrathecal immune response in elderly patients with non-multiple sclerosis chronic autoimmune-inflammatory neurological diseases - a retrospective cross-sectional study","volume":"14","author":"Brauchle","year":"2023","journal-title":"Front neurol"},{"key":"B29","volume-title":"Modern epidemiology","author":"Rothman KJ","year":"2008"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/135245859800400302","article-title":"Cerebrospinal fluid\u2013physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases","volume":"4","author":"Reiber","year":"1998","journal-title":"Mult Scler"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/37.7.1153","article-title":"Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain","volume":"37","author":"Reiber","year":"1991","journal-title":"Clin Chem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-510X(94)90298-4","article-title":"Flow rate of cerebrospinal fluid (CSF)\u2013a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases","volume":"122","author":"Reiber","year":"1994","journal-title":"J Neurol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9229","DOI":"10.1038\/s41598-022-13042-2","article-title":"A systematic review and meta-analysis of HLA class II associations in patients with IgG4 autoimmunity","volume":"12","author":"Panhuber","year":"2022","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/ane.2018.138.issue-3","article-title":"HLA and MuSK-positive myasthenia gravis: A systemic review and meta-analysis","volume":"138","author":"Hong","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2017.1385622","article-title":"Association between HLA-DQB1 polymorphisms and pemphigus vulgaris: A meta-analysis","volume":"47","author":"Li","year":"2018","journal-title":"Immunol Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605214","article-title":"Common denominators in the immunobiology of igG4 autoimmune diseases: what do glomerulonephritis, pemphigus vulgaris, myasthenia gravis, thrombotic thrombocytopenic purpura and autoimmune encephalitis have in common","volume":"11","author":"Koneczny","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae048","article-title":"HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease","author":"Yogeshwar","year":"2024","journal-title":"Brain"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26608","article-title":"Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies","volume":"31","author":"Bruggemann","year":"2016","journal-title":"Move Disord"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-201105","article-title":"Hypothalamic-bulbar MRI hyperintensity in anti-igLON5 disease with serum-restricted antibodies: A case report and systematic review of literature","volume":"79","author":"Tagliapietra","year":"2021","journal-title":"J Alzheimer\u2019s dis: JAD"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.589466","article-title":"Figural memory impairment in conjunction with neuropsychiatric symptoms in igLON5 antibody-associated autoimmune encephalitis","volume":"11","author":"Hansen","year":"2020","journal-title":"Front Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000974","article-title":"Clinical and prognostic value of immunogenetic characteristics in anti-LGI1 encephalitis","volume":"8","author":"Muniz-Castrillo","year":"2021","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25666","article-title":"Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability","volume":"87","author":"Kornau","year":"2020","journal-title":"Ann Neurol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000669","article-title":"Intrathecal B-cell activation in LGI1 antibody encephalitis","volume":"7","author":"Lehmann-Horn","year":"2020","journal-title":"Neurology(R) neuroimmunol Neuroinflamm"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001062","article-title":"Intrathecal antibody production against epstein-barr, herpes simplex, and other neurotropic viruses in autoimmune encephalitis","volume":"8","author":"Schwenkenbecher","year":"2021","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010854","article-title":"Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis","volume":"95","author":"Spatola","year":"2020","journal-title":"Neurology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26223","article-title":"Neuropathological variability within a spectrum of NMDAR-encephalitis","volume":"90","author":"Zrzavy","year":"2021","journal-title":"Ann Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1376456\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T04:52:49Z","timestamp":1715835169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1376456\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2024.1376456"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1376456","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"article-number":"1376456"}}